Post by kickingfrog on Mar 11, 2013 12:09:26 GMT
Osteoporosis Associated with Neutralizing
Autoantibodies against Osteoprotegerin
Philip L. Riches, M.R.C.P., Euan McRorie, F.R.C.P.,
William D. Fraser, Ph.D., F.R.C.Path., Catherine Determann, B.Med.Sci.,
Rob van’t Hof, Ph.D., and Stuart H. Ralston, M.D.
From the Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine,
University of Edinburgh, Western General
Hospital, Edinburgh (P.L.R., E.M., C.D.,
R.H., S.H.R.); and the Unit of Clinical
Chemistry, School of Clinical Sciences,
University of Liverpool, Liverpool (W.D.F.)
— both in the United Kingdom.
.....
N Engl J Med 2009;361:1459-65.
Copyright © 2009 Massachusetts Medical Society.
Summary
Autoantibodies against osteoprotegerin, which block the inhibitory effect of osteoprotegerin on signaling by the receptor activator of nuclear factor (NF)-κB (RANK),
were identified in a man with celiac disease who presented with severe osteoporosis
and high bone turnover.
The osteoporosis did not respond to the treatment of his
celiac disease but was completely reversed by bisphosphonate therapy.
Autoantibodies
against osteoprotegerin were detected in three additional patients with celiac disease.
Such autoantibodies may be associated with the development of high-turnover
osteoporosis, but whether autoantibodies against osteoprotegerin commonly contribute to the pathogenesis of osteoporosis in patients with celiac disease remains
to be determined.
www.nejm.org/doi/pdf/10.1056/NEJMoa0810925
Autoantibodies against Osteoprotegerin
Philip L. Riches, M.R.C.P., Euan McRorie, F.R.C.P.,
William D. Fraser, Ph.D., F.R.C.Path., Catherine Determann, B.Med.Sci.,
Rob van’t Hof, Ph.D., and Stuart H. Ralston, M.D.
From the Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine,
University of Edinburgh, Western General
Hospital, Edinburgh (P.L.R., E.M., C.D.,
R.H., S.H.R.); and the Unit of Clinical
Chemistry, School of Clinical Sciences,
University of Liverpool, Liverpool (W.D.F.)
— both in the United Kingdom.
.....
N Engl J Med 2009;361:1459-65.
Copyright © 2009 Massachusetts Medical Society.
Summary
Autoantibodies against osteoprotegerin, which block the inhibitory effect of osteoprotegerin on signaling by the receptor activator of nuclear factor (NF)-κB (RANK),
were identified in a man with celiac disease who presented with severe osteoporosis
and high bone turnover.
The osteoporosis did not respond to the treatment of his
celiac disease but was completely reversed by bisphosphonate therapy.
Autoantibodies
against osteoprotegerin were detected in three additional patients with celiac disease.
Such autoantibodies may be associated with the development of high-turnover
osteoporosis, but whether autoantibodies against osteoprotegerin commonly contribute to the pathogenesis of osteoporosis in patients with celiac disease remains
to be determined.
www.nejm.org/doi/pdf/10.1056/NEJMoa0810925